Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02528201
Other study ID # COXA-0508-247
Secondary ID A3191099
Status Completed
Phase Phase 4
First received June 18, 2015
Last updated August 18, 2015
Start date September 2002
Est. completion date November 2004

Study information

Verified date August 2015
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority Norway: Regional Ethics Committee
Study type Interventional

Clinical Trial Summary

A clinical trial to assess the effect of celecoxib 200 milligrams (mg) once daily and 400 milligrams (mg) once daily compared to diclofenac three times daily in the treatment of Ankylosing Spondylitis (AS) for 12 weeks. This will be used to confirm the results of a prior 6 week trial.


Recruitment information / eligibility

Status Completed
Enrollment 330
Est. completion date November 2004
Est. primary completion date November 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Male or female, 18 to 75 years of age, inclusive.

- Clinical diagnosis of ankylosing spondylitis:

- Willing to stop existing NSAID/COX-2 inhibitor treatment for up to two weeks.

- Having given written informed consent to participate in the trial.

- Pain intensity = 40 mm on the visual analog scale, worsening by at least 30 % compared to that recorded at the screening visit.

- Last administration of analgesic without anti-inflammatory activity is = 8 h, the last administration of long-acting NSAIDs is = 72 h

Exclusion Criteria:

- Patients with acute peripheral articular disease (defined by the onset within 4 weeks prior to visit

- Known inflammatory enteropathy (e.g. ulcerative colitis, Crohn's disease).

- Ongoing extra-articular signs (e.g. cardiac involvement).

- Current painful vertebral compression.

- Requirement to start physiotherapy, re-education or manipulation

- History of clinical gastroduodenal ulcer in the year preceding inclusion, confirmed by endoscopy; continuing gastro-intestinal bleeding.

- Cardiac failure or known renal insufficiency that could be affected by study medication, chronic or acute hepatic insufficiency, significant coagulation disorders or history of asthma.

- Current or history of malignancy (except: patients having a basal cell carcinoma or other malignancy operated on and in remission for 5 years before inclusion in the trial).

- Pregnancy, women of childbearing potential not using adequate contraceptive methods or nursing mothers.

- Subject who has evidence of alcohol or drug abuse.

- Participation in any other clinical study within 30 days prior to the screening visit.

- Any condition that would prevent the patient from entering the study, according to the investigator's judgment.

- Known hypersensitivity to celecoxib, sulphonamides or any NSAID (including salicylic acid).

- Taking the following medications: Muscle relaxants, hypnotic, anxiolytics, sedatives, tranquillizers or antidepressants (unless stable for 2 weeks before screening and continuing throughout the trial), NSAIDs or COX-2 inhibitors other than study medication, acetylsalicylic acid (ASA) > 160 mg /day, anti-coagulants, ticlopidine, lithium, anti-TNF agents or methotrexate > 15 mg/week (Note: ASA = 160 mg/day for cardioprotection is permitted), Use of oral or systemic analgesic medication, except from paracetamol, within 3 days of study entry and through the study, Corticosteroids (PO/IM/IV/IA) in the 6 weeks preceding inclusion in the trial, Anti-ulcer medication including chronic (daily or almost daily) use of antacids [Note: Occasional use of antacids during the study will be permitted.]

- Change in dose of a slow-acting drug (e.g. sulfasalazin, methotrexate) in the past 60 days preceding inclusion in the trial.

- Taking paracetamol > 2000 mg/day (including during the screening period).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Celecoxib 200 milligrams
Celecoxib 200 milligrams once a day
Celecoxib 400 milligrams
Celecoxib 400 milligrams once a day
diclofenac 50 milligrams
diclofenac 50 milligrams three times a day

Locations

Country Name City State
Norway Ålesund sykehus Ålesund
Norway Martina Hansens hospital Bærum Postterminal
Norway Bekkestua legesenter Bekkestua
Norway Dr. Johannessen Kontor Bergen
Norway Dr.Wiigs kontor Bergen
Norway Nordland Medisinske Senter Bodø
Norway Sykehuset Buskerud HF Drammen
Norway Lægene på Kongens torv Gamle Fredrikstad
Norway Centre For Clinical Trials Hamar
Norway Harstad sykehus Harstad
Norway Haugesund sanitetsforenings revmatismesykehus Haugesund
Norway Horten legesenter Horten
Norway Solli Klinikk AS Jessheim
Norway Kongsvinger sykehus HF Kongsvinger
Norway Dr. Svensens kontor Kristiansand
Norway Vest-Agder sentralsykehus Kristiansand
Norway Lensbygda Legekontor Lena
Norway Helse Nord-Trøndelag HF, Sykehuset Levanger Levanger
Norway LSF Reumatismesykehus Lillehammer
Norway Helgelandssykehuset HF Mo I Rana
Norway Diakonhjemmet Hospital Oslo
Norway Økernlegene Oslo
Norway Rikshospitalet Oslo
Norway Betanien Hospital Skien
Norway Rosten legesenter Tiller
Norway Universitetssykehuset Nord-Norge HF Tromsø
Norway St.Olavs Hospital Trondheim

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in baseline of Patient Global Assessment of Pain Intensity (VAS) at week 12 Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain. Baseline, Week 12 No
Secondary Participants Global Assessment of Pain Intensity (VAS) Global Pain Intensity score (VAS): is a participant reported assessment of pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm= no pain and 100=most severe pain. Weeks 2, 6 No
Secondary Bath Ankylosing Spondylitis Functional Index (BASFI) BASFI is a validated self assessment tool that determines the degree of functional limitation in AS. Utilizing a VAS of 0-10 (0 = easy, 10 = impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions. Weeks 2, 6 No
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) BASDAI is a validated self assessment tool used to determine disease activity in participant with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0-10 Weeks 2, 6 No
Secondary Participants and Physicians Global Assessment of Disease Activity Participants are asked at each visit the following questions: Taking everything into account how do you assess the activity of your disease in the last 2 days on a scale where: 0=disease inactive with no symptoms and 100=disease extremely active? Weeks 2, 6, 12 No
Secondary Participants and Physicians Global Assessment of Treatment The patients will be asked up to four global questions about safety and efficacy of the trial medication and about their current disease status. Responses are done on a 5 point scale where 0=no effect, 1=poor effect, 2=moderate effect, 3=good effect, and 4=excellent. At the same visits the investigator will be asked to do his/her own judgment of the efficacy and tolerance of the treatment (excellent, good, moderate, poor). Week 12 No
Secondary Participants Consumption of Rescue Medication Participant consumption of rescue medication (paracetamol) calculated at each individual visit (except from the screening visit) by counting returned tablets versus tablets dispensed at the previous visit. Baseline, Weeks 2, 6, 12 No
See also
  Status Clinical Trial Phase
Terminated NCT02685904 - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis Phase 3
Completed NCT02186873 - A Study of Golimumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT01668004 - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Phase 4
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01934933 - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Phase 4
Not yet recruiting NCT04875299 - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed NCT02763111 - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis Phase 2
Completed NCT02758782 - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Phase 4
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT01750528 - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis N/A
Completed NCT01463189 - Web-based Support to Manage Arthritis Pain Phase 2
Completed NCT01091675 - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs Phase 3
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Recruiting NCT00747578 - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan N/A
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Completed NCT00715091 - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Phase 4
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00367211 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Phase 3
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4